Cargando…
Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: A case report
BACKGROUND: Elderly-onset neuromyelitis optica spectrum disorder (NMOSD) is a rare entity that poses a therapeutic challenge. We report a case of elderly-onset NMOSD with mutant FCGR3A genotype who was successfully treated with ofatumumab after multiple episodes of relapse. CASE REPORT: The patient...
Autores principales: | Zhang, Weihe, Jiao, Yujuan, Jiao, Jinsong, Jin, Ming, Peng, Dantao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773878/ https://www.ncbi.nlm.nih.gov/pubmed/36569904 http://dx.doi.org/10.3389/fimmu.2022.1047992 |
Ejemplares similares
-
Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders
por: Marcinnò, Andrea, et al.
Publicado: (2018) -
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
por: Farhat, Lara, et al.
Publicado: (2018) -
Therapeutic efficacy and safety of plasmapheresis in elderly patients with neuromyelitis optica spectrum disorder: a single-center observational study
por: Zhang, Weihe, et al.
Publicado: (2023) -
Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study
por: Jiao, Yujuan, et al.
Publicado: (2018) -
Rituximab-Induced Hypogammaglobulinemia and Risk of Infection in Neuromyelitis Optica Spectrum Disorders: A 14-Year Real-Life Experience
por: Kim, Su-Hyun, et al.
Publicado: (2022)